Parkinson's Disease in Women

Parkinson's disease affects approximately 400,000 women in the United States, though women are diagnosed about 1.5 times less frequently than men. Women with Parkinson's tend to develop the disease later, are more likely to present with tremor as the first symptom, experience higher rates of depression and pain, and face longer diagnostic delays. Estrogen appears to play a neuroprotective role, which may partly explain the sex difference in incidence.

Parkinson's disease research has historically been dominated by studies of men. Most clinical trials have enrolled predominantly male participants, clinical rating scales were developed and validated in largely male populations, and the “typical” presentation of Parkinson's disease described in medical textbooks reflects the male experience. This matters because women with Parkinson's often experience the disease differently — in its onset, its symptoms, its progression, its treatment response, and its impact on daily life.

Why Women Get Parkinson's Less Often

The sex difference in Parkinson's disease incidence — approximately 1.5 men for every 1 woman diagnosed — is one of the most consistent findings in PD epidemiology and suggests biological factors play a role in disease susceptibility.

The Estrogen Hypothesis

The leading explanation involves estrogen's neuroprotective effects. Estrogen receptors are present in the substantia nigra and striatum — the very brain regions most affected in Parkinson's disease. Research has demonstrated several mechanisms by which estrogen may protect dopaminergic neurons:

• Antioxidant effects. Estrogen reduces oxidative stress, one of the key drivers of dopaminergic neuron death. It acts as a free radical scavenger and upregulates the brain's endogenous antioxidant defenses.
• Anti-inflammatory properties. Estrogen modulates microglial activation and reduces neuroinflammation, which is increasingly recognized as a contributor to PD progression.
• Dopamine system support. Estrogen promotes dopamine synthesis, inhibits dopamine reuptake, and reduces dopamine catabolism — effectively boosting dopamine signaling in the nigrostriatal pathway.
• Mitochondrial protection. Estrogen supports mitochondrial function and inhibits mitochondrial pathways of cell death.

Supporting the estrogen hypothesis, epidemiological studies have found that women who undergo early oophorectomy (surgical removal of the ovaries before natural menopause) have an increased risk of parkinsonism. Women with a longer cumulative lifetime exposure to estrogen — through later menopause, use of oral contraceptives, or hormone replacement therapy — tend to have a lower risk, though the data on hormone replacement therapy are mixed and not conclusive enough to recommend HRT for PD prevention.

How Symptoms Differ in Women

Women with Parkinson's disease tend to present with a distinct symptom profile compared to men. These differences have implications for diagnosis, treatment, and quality of life:

Motor Symptoms

• Tremor dominance. Women are significantly more likely than men to present with tremor as their primary motor symptom. The tremor-dominant subtype of Parkinson's is generally associated with slower disease progression and a more favorable prognosis than the postural instability and gait difficulty (PIGD) subtype, which is more common in men.
• Greater levodopa-induced dyskinesia. Women are more susceptible to developing dyskinesias (involuntary movements) as a complication of levodopa therapy, possibly due to differences in body weight, body composition, and drug metabolism. This can significantly affect quality of life and may require earlier adjustment of medication strategies.
• Later motor symptom onset. On average, women develop motor symptoms approximately two years later than men, which may be related to the protective effect of estrogen during the premenopausal years.

Non-Motor Symptoms

• Depression and anxiety. Women with Parkinson's report significantly higher rates of depression and anxiety compared to men with the disease. This is not solely a reaction to diagnosis — it reflects sex differences in the serotonergic and noradrenergic systems that are affected by PD neurodegeneration.
• Pain. Women with Parkinson's report more pain than men, including musculoskeletal pain, neuropathic pain, and pain related to dystonia. Pain is one of the most underrecognized non-motor symptoms and significantly impacts daily functioning.
• Fatigue. Women report higher levels of fatigue than men, which compounds the challenges of managing motor symptoms and maintaining daily activities.
• Constipation. While constipation is common in both sexes, women with Parkinson's may experience it more severely, potentially compounded by pelvic floor dysfunction.
• Urinary and pelvic floor symptoms. Urinary urgency, frequency, and incontinence are common in women with PD, and pelvic floor dysfunction can significantly affect quality of life. These symptoms are often underreported and undertreated.

Diagnostic Disparities

Women with Parkinson's face longer diagnostic delays and higher rates of misdiagnosis compared to men. Several factors contribute to this disparity:

• Atypical presentation. Because the “classic” presentation of Parkinson's (as taught in medical schools and described in clinical references) is based predominantly on male cases, women whose symptoms do not fit this pattern may not be immediately recognized.
• Symptom overlap with other conditions. Depression, anxiety, fatigue, and pain — which are often prominent in women with PD — may be attributed to other conditions (menopause, fibromyalgia, stress, depression) rather than being recognized as potential PD non-motor symptoms.
• Referral bias. Studies have found that women are less likely to be referred to a movement disorder specialist even when they present with the same symptoms as men. When women are referred, they tend to be at a more advanced stage.
• Self-reporting differences. Women may describe their symptoms differently than men, using terms that are less easily mapped to standard diagnostic criteria. They may also be more likely to attribute early symptoms to aging or stress.

Menopause and Parkinson's

Menopause represents a pivotal transition for women with or at risk for Parkinson's disease. The dramatic decline in estrogen that occurs during menopause removes a key neuroprotective factor, and many women report that their Parkinson's symptoms worsen around the time of menopause.

• Symptom fluctuation during perimenopause. The years leading up to menopause (perimenopause), when estrogen levels fluctuate dramatically, can cause unpredictable changes in Parkinson's symptoms. Motor fluctuations may worsen, non-motor symptoms (particularly mood, sleep, and fatigue) may intensify, and medication effectiveness may become less predictable.
• Post-menopause symptom acceleration. Some women report a noticeable worsening of PD symptoms after menopause, though this is difficult to separate from the natural progression of the disease, which occurs on a similar timeline.
• Hormone replacement therapy (HRT). The data on HRT for women with Parkinson's disease are mixed and insufficient to make clear recommendations. Some observational studies suggest that HRT may provide modest symptom benefit, while others show no effect or potential harm. The decision to use HRT should be made with your gynecologist and neurologist together, weighing the overall risks and benefits for your individual health profile. HRT should not be used specifically to treat Parkinson's.
• Bone health. Menopause accelerates bone loss, and women with Parkinson's are already at elevated risk for falls due to postural instability and balance impairment. The combination creates a high risk for fractures, particularly hip fractures. Bone density screening and proactive management of osteoporosis are essential.

Pregnancy and Parkinson's

While Parkinson's disease most commonly affects people over 60, approximately 5 to 10 percent of cases are young-onset (diagnosed before age 50), and some women of childbearing age have PD. Pregnancy with Parkinson's raises important considerations:

• Medication safety. Many Parkinson's medications have not been adequately studied in pregnancy. Levodopa/carbidopa, while in widespread use, has limited pregnancy safety data. Dopamine agonists may suppress lactation. Any pregnancy in a woman with Parkinson's should be planned in close coordination with both a movement disorder specialist and a high-risk obstetrician. Medication adjustments may be needed before conception and throughout pregnancy.
• Hormonal effects on symptoms. Pregnancy-related increases in estrogen may temporarily improve Parkinson's symptoms in some women, though this is variable and unpredictable. Conversely, the postpartum period — when estrogen drops precipitously — may bring symptom worsening.
• Genetic counseling. Women with young-onset Parkinson's may want to discuss genetic testing and counseling before or during pregnancy. While most PD is not inherited in a simple Mendelian pattern, certain genetic variants (GBA1, LRRK2, PINK1) carry an elevated risk that may be relevant for family planning decisions.

Treatment Considerations for Women

While the fundamental treatment approach for Parkinson's disease is the same regardless of sex, several factors deserve specific attention in women:

• Levodopa dosing. Women generally have lower body weight than men, which may require starting at lower doses. Women are also more prone to levodopa-induced dyskinesia, which may require earlier use of extended-release formulations or adjunctive therapies to smooth out motor fluctuations.
• Depression and anxiety treatment. Given the higher rates of depression and anxiety in women with PD, screening should be routine and treatment proactive. SSRIs and SNRIs are commonly used, but potential interactions with Parkinson's medications (particularly MAO-B inhibitors) must be carefully considered.
• Pain management. Women's pain symptoms in PD are frequently undertreated. A comprehensive pain assessment should distinguish between PD-related pain (dystonic, musculoskeletal, neuropathic, central) and non-PD causes.
• Pelvic floor therapy. Pelvic floor physical therapy can be beneficial for urinary symptoms and pelvic floor dysfunction, which disproportionately affect women with PD.
• Exercise. The evidence for exercise in Parkinson's applies equally to women, but barriers to exercise participation may differ. Women may face greater caregiving responsibilities that limit exercise time, and body image concerns related to visible symptoms may create reluctance to exercise in group settings. Women-only PD exercise programs are available in some communities.
• Social support. Women with Parkinson's often report a different social experience than men. Women are more likely to be primary caregivers for others (spouses, aging parents, grandchildren) even while managing their own disease. Support groups specifically for women with PD can provide targeted resources and community.

Research Gaps and Future Directions

The underrepresentation of women in Parkinson's research has real consequences. Clinical trials have historically enrolled as few as 20 to 30 percent female participants, meaning that the efficacy and side effect profiles of many PD medications are based predominantly on data from men.

Several important research questions remain unanswered:

• Should levodopa dosing guidelines be adjusted for sex and body weight?
• Can hormone-based interventions reduce PD risk or slow progression in women?
• Why do women experience higher rates of dyskinesia, and can this be prevented?
• How does PD interact with pregnancy, lactation, and the postpartum period?
• Are the neuroprotective benefits of exercise equally strong in women?

Encouraging developments include the Parkinson's Foundation's Women and PD initiative, which funds research specifically addressing sex and gender differences, and growing requirements from the NIH and FDA for adequate representation of women in clinical trials. As our understanding of sex-specific disease mechanisms improves, treatment recommendations may become increasingly personalized.

What Women with Parkinson's Can Do Now

• Advocate for yourself. If you feel your symptoms are being dismissed or attributed to other causes, seek a second opinion from a movement disorder specialist. Diagnostic delay has real consequences.
• Discuss sex-specific concerns with your specialist. Ask about dyskinesia risk when starting or adjusting levodopa, discuss bone health and fall prevention, and bring up any urinary or pelvic floor symptoms.
• Prioritize mental health. Screen regularly for depression and anxiety. Seek treatment early — these are not signs of weakness but neurochemical consequences of the disease itself.
• Plan for menopause. If you are premenopausal or perimenopausal, have a proactive conversation with your neurologist and gynecologist about what to expect and how to manage potential symptom changes.
• Connect with other women with PD. The Parkinson's Foundation and other organizations offer support groups, webinars, and resources specifically for women.
• Consider participating in research. Women's participation in clinical trials is critically needed to improve outcomes for all women with Parkinson's. The Michael J. Fox Foundation's Fox Trial Finder can help match you with appropriate studies.

Parkinson's Foundation Helpline: 1-800-4PD-INFO (1-800-473-4636), Monday through Friday, 9 AM to 7 PM ET. Specialists can help with questions about sex-specific concerns, referrals, and resources.